News Archive

2017

September

Media Release / Sep 22, 2017

Novartis and The Max Foundation transform pioneering cancer access program for people in lower-income countries

Read More
Media Release / Sep 20, 2017

Novartis drug Rydapt® (midostaurin) receives EU approval for newly diagnosed FLT3-mutated acute myeloid leukemia (AML) and three types of advanced systemic mastocytosis (SM)

Read More
Media Release / Sep 16, 2017

Novartis' Xolair® confirms re-treatment efficacy in chronic spontaneous urticaria patients after treatment interruption

Read More
Media Release / Sep 14, 2017

Sandoz proposed biosimilar adalimumab matches reference biologic in terms of efficacy and safety in long-term study

Read More
Media Release / Sep 13, 2017

Novartis' Cosentyx® sets new benchmark in psoriasis with robust 5-year sustained Phase III efficacy and safety data

Read More
Media Release / Sep 12, 2017

Sandoz proposed biosimilar rituximab accepted for review by the FDA

Read More
Media Release / Sep 11, 2017

Novartis Phase III study demonstrates adjuvant Tafinlar® + Mekinist® reduced the risk of disease recurrence by 53% in patients with resected BRAF V600 mutation-positive melanoma

Read More
Media Release / Sep 09, 2017

Novartis presents new data at EURETINA 2017 confirming Lucentis® efficacy and durability vs aflibercept

Read More
Media Release / Sep 07, 2017

Novartis presents new analysis demonstrating AMG 334 (erenumab) significantly reduced monthly migraine days in patients who failed previous preventive therapies

Read More
Media Release / Sep 05, 2017

Novartis landmark Phase III trial shows fingolimod significantly reduces relapses in children and adolescents with MS

Read More

Pages

Related Links

Annual Report 2016

Review the strategy and annual performance of Novartis and read letters from our Chairman and CEO.

Learn More

Contact Media Relations

For media and journalist inquiries, please contact the Novartis Corporate Media Relations office by email or telephone.

Central Media Line:
Phone: +41 61 324 2200